
|Videos|August 24, 2020
Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy
Author(s)Targeted Oncology
Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Survey Finds Persistent Cancer Drug Shortages Across US Centers
2
Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma
3
Rewriting the Playbook: How Biomarker-Driven Therapy Is Transforming Metastatic Prostate Cancer Care
4
FDA Delays Decision on Zanzalintinib Combo for mCRC
5



































